- Stock: Pre-Order
- Brand: Novo Nordisk
- Product ID: Insulin Degludec + Insulin Aspart Premixed
100% Secure Payment
bKash | Nagad | Cards via SSLCommerz | COD
Monthly Medicines Available | Free Delivery on Eligible Orders
This Item is for pre order
Ryzodeg FlexTouch – Insulin Degludec/Aspart 100 IU/ml by Novo Nordisk
| Generic Name | Insulin Degludec / Insulin Aspart (IDegAsp) |
| Brand Name | Ryzodeg 70/30 |
| Manufacturer | Novo Nordisk A/S (Denmark) |
| Dosage Form | Solution for Injection — Pre-filled FlexTouch Pen (3 ml) |
| Strength | 100 IU/ml (70 IU degludec + 30 IU aspart per ml) |
| Pack Size | 5 FlexTouch pens × 3 ml = 1,500 IU total |
| Drug Class | Co-formulation: Ultra-long Basal + Rapid-acting Mealtime Insulin |
| Prescription Required | Yes — Rx Only |
| Onset / Duration | Aspart: onset 10–20 min | Degludec: duration >42 hrs (peakless) |
What is Ryzodeg FlexTouch?
Ryzodeg 70/30 FlexTouch is Novo Nordisk's unique co-formulation insulin combining two separate components in a single injection: 70% insulin degludec (ultra-long-acting basal, >42 hours) and 30% insulin aspart (rapid-acting, 3–5 hours). Unlike premixed suspensions (NovoMix 30), this is a clear solution — both insulins co-exist as separate molecules retaining their individual pharmacokinetic profiles after injection. Patients get both a peakless ultra-long basal component AND rapid mealtime coverage from a single FlexTouch pen injection. This pack contains 5 FlexTouch pens × 3 ml, with 1-unit dose steps.
Generic Name & Composition
Each ml: 70 IU insulin degludec (ultra-long basal) + 30 IU insulin aspart (rapid-acting). Both co-exist in solution without interacting. After injection: degludec forms multi-hexameric depot dissolving over 42+ hours (flat basal coverage); aspart monomers absorbed rapidly (10–20 min) for post-meal control. This co-formulation technology is unique to Novo Nordisk (IDegAsp).
Indications
- Type 2 diabetes — once or twice daily covering both basal and mealtime needs
- Patients with regular meal timing simplifying from 2-pen to 1-pen regimen
- Intensification from basal-only to basal-plus
- Type 1 diabetes — in select cases under specialist guidance
How It Works — Mechanism of Action
Degludec (70%): Soluble multi-hexameric chains in subcutaneous tissue dissolve slowly over 42+ hours — steady peakless basal coverage. Aspart (30%): Rapidly absorbed as monomers (onset 10–20 min, peak 1–3 hrs, duration 3–5 hrs) — post-meal glucose control. Both activate insulin receptors: GLUT-4 uptake, hepatic glucose suppression, glycogen and lipid synthesis.
Dosage & Administration
Regimen: Once or twice daily injected with main meal(s). Starting dose: 10 IU once daily with largest meal; titrate by 2 IU every 3–4 days. FlexTouch: Solution is clear — no resuspension. Dial dose, inject subcutaneously, hold 6 seconds. Rotate sites (abdomen, thigh, upper arm).
Side Effects
Very common: Hypoglycaemia — from aspart component post-meal and/or degludec overnight.
Common: Injection site reactions, weight gain, lipohypertrophy.
Uncommon: Lipoatrophy, peripheral oedema.
Rare: Anaphylaxis, severe allergic reactions.
Drug Interactions
Increase hypoglycaemia: Oral antidiabetics, GLP-1 agonists, SGLT-2 inhibitors, ACE inhibitors, MAO inhibitors, alcohol, salicylates.
Reduce effect: Corticosteroids, glucagon, thyroid hormones, thiazides, sympathomimetics, oral contraceptives.
Caution: Beta-blockers mask hypoglycaemia symptoms.
Contraindications
- Hypersensitivity to insulin degludec, aspart, or any excipient
- Active hypoglycaemia; do not mix with other insulins
Pregnancy & Lactation
Pregnancy: Limited data; alternative insulins with established pregnancy safety often preferred under specialist guidance. Lactation: Not expected at significant concentrations in breast milk.
Precautions & Warnings
- Clear solution — do NOT roll or shake. If cloudy, do not use.
- Inject with meal: Aspart acts within 10–20 min — eat within 15 minutes.
- Steady state in 2–3 days: Avoid over-titration in first days.
Overdose
Hypoglycaemia. Degludec extends risk beyond 24 hours. Mild: oral glucose. Severe: IV dextrose or IM glucagon. Extended monitoring required.
Storage Instructions
- Unopened: 2–8°C. Do not freeze.
- In-use pen: Below 30°C. Do not refrigerate.
- Discard 56 days after first use.
Frequently Asked Questions (FAQs)
Q1: How is Ryzodeg different from NovoMix 30?
Ryzodeg uses ultra-long degludec (>42 hrs) + rapid aspart as a clear solution. NovoMix 30 uses intermediate protamine-aspart + rapid aspart as a cloudy suspension requiring resuspension. Ryzodeg provides true 24-hour+ basal coverage; NovoMix 30 does not.
Q2: Do I need to roll or shake Ryzodeg before injection?
No — Ryzodeg is a clear solution. Dial dose and inject directly. If cloudy, do not use.
Q3: Can Ryzodeg replace two separate insulin pens?
For once-daily mealtime + basal regimens, yes. If multiple mealtime injections are needed, additional NovoRapid may be required for additional meals.
Q4: Who manufactures Ryzodeg?
Novo Nordisk A/S (Denmark). Ryzodeg (IDegAsp) is a proprietary co-formulation unique to Novo Nordisk.
⚕ Medical Disclaimer: For educational purposes only. Ryzodeg is Rx-only. Consult your diabetologist before changing insulin therapy. DiabetesStore.com.bd is a licensed online pharmacy.
